Stockreport

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]

Zenas BioPharma, Inc.  (ZBIO) 
PDF -Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD)- -Advancing multiple obe [Read more]